Targeting Nrf2 Signaling Pathway in Cancer Prevention and Treatment: The Role of Cannabis Compounds.
Anna RybarczykAleksandra Majchrzak-CelińskaVioletta Krajka-KuzniakPublished in: Antioxidants (Basel, Switzerland) (2023)
The development and progression of cancer are associated with the dysregulation of multiple pathways involved in cell proliferation and survival, as well as dysfunction in redox balance, immune response, and inflammation. The master antioxidant pathway, known as the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, regulates the cellular defense against oxidative stress and inflammation, making it a promising cancer prevention and treatment target. Cannabinoids have demonstrated anti-tumor and anti-inflammatory properties, affecting signaling pathways, including Nrf2. Increased oxidative stress following exposure to anti-cancer therapy prompts cancer cells to activate antioxidant mechanisms. This indicates the dual effect of Nrf2 in cancer cells-influencing proliferation and apoptotic processes and protecting against the toxicity of anti-cancer therapy. Therefore, understanding the complex role of cannabinoids in modulating Nrf2 might shed light on its potential implementation as an anti-cancer support. In this review, we aim to highlight the impact of cannabinoids on Nrf2-related factors, with a focus on cancer prevention and treatment. Additionally, we have presented the results of several research studies that combined cannabidiol (CBD) with other compounds targeting Nrf2. Further studies should be directed toward exploring the anti-inflammatory effects of cannabinoids in the context of cancer prevention and therapy.
Keyphrases
- oxidative stress
- papillary thyroid
- signaling pathway
- cancer therapy
- anti inflammatory
- induced apoptosis
- dna damage
- diabetic rats
- ischemia reperfusion injury
- squamous cell
- immune response
- nuclear factor
- drug delivery
- healthcare
- primary care
- pi k akt
- toll like receptor
- lymph node metastasis
- stem cells
- dendritic cells
- inflammatory response
- combination therapy
- case control